Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
prostaglandin analog |
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
S01EE03
|
| gptkbp:brand |
gptkb:Latisse
gptkb:Lumigan |
| gptkbp:CASNumber |
155206-00-1
|
| gptkbp:chemicalFormula |
C25H37NO4
|
| gptkbp:discoveredBy |
gptkb:Allergan
|
| gptkbp:eliminationHalfLife |
45 minutes
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
bimatoprost
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
reduces intraocular pressure by increasing outflow of aqueous humor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201197
5311236 DB00905 |
| gptkbp:routeOfAdministration |
ophthalmic
|
| gptkbp:sideEffect |
eye redness
darkening of eyelid skin increased brown pigmentation of the iris eye itching |
| gptkbp:UNII |
Q3T9TXL6V2
|
| gptkbp:usedFor |
treatment of glaucoma
eyelash growth treatment of ocular hypertension |
| gptkbp:bfsParent |
gptkb:Latisse
|
| gptkbp:bfsLayer |
7
|